Pacific Edge

Greater confidence in the risk stratification and surveillance of bladder cancer

A redirector page has been set up without anywhere to redirect to.

Pacific Edge offers opportunities for growth in a dynamic company focused on cancer diagnostics.

Pacific Edge’s Board includes members with experience in healthcare, biotechnology, investment, and governance, guiding the company’s strategy and supporting its growth in diagnostic technologies.

Pacific Edge has a clinical advisory board to provide expert advice on global clinical needs and applications for the Cxbladder technology

Pacific Edge is supported by an internationally renowned team of scientific advisors.

Established in 2001, Pacific Edge develops diagnostic and prognostic tools for cancer that are easy to use, non invasive and highly accurate.

Pacific Edge is committed to conducting business the right way, ethically and in line with legal and regulatory obligations. The Board believes that strong corporate governance principles help to manage risks, provide transparency and protect the interests of shareholders and stakeholders.

Cxbladder was first introduced to the New Zealand market in 2011 through Pacific Edge Diagnostics NZ (PEDNZ), a wholly owned subsidiary of Pacific Edge Ltd.

Pacific Edge aims to improve early cancer diagnosis and treatment through innovative solutions for global communities.

Innovative solutions for cancer diagnostics.

Pacific Edge confirms Medicare now covers **Cxbladder Triage** and **Triage Plus**, urine-based biomarker tests for patients with microhematuria. The final Local Coverage Determination (LCD) was published to the Medicare Coverage Database, expanding reimbursement for these diagnostic tools. The tests aid in assessing bladder cancer risk in at-risk patients.

Nov 2026Pacific EdgeNews article

Pacific Edge reports progress in its US commercial recovery efforts. The company’s Q2 2027 Investor Update highlights updates on operational and strategic developments, though specific details remain undisclosed.

Oct 2026Pacific EdgeNews article

Pacific Edge names Willy Iglesias as Chief Digital Officer to advance its leadership in bladder cancer diagnostics. The move aligns with the company’s focus on maintaining its early-mover position in the field. Iglesias will oversee digital strategy and innovation initiatives.

Aug 2026Pacific EdgeNews article

Pacific Edge’s APAC operations are nearing profitability as commercial test volumes rise. The company’s next-generation test, **Cxbladder Triage Plus**, sees growing adoption in the region. These trends support cost efficiency and revenue growth for the business.

Jul 2026Pacific EdgeNews article